1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025

Report Details
Treating diabetes – benefit your influence by finding new R&D trends and sales prospects
Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities.

Visiongain’s updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what’s possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines’ predicted revenue.

Forecasts to 2025 and other analyses explain and predict the diabetes treatment market
Why miss crucial data that you need? Why struggle to find information? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.

Our study also shows 90 tables, 91 charts and two interviews. Our work’s purpose is to predict that industry’s future, helping your research, analyses and decisions. See how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities exist.

Forecasting of the world diabetes drugs market and its segments – what does the future hold?
What are the secrets of the industry's progress? Where’s it heading? Discover in our report overall world revenue prediction to 2025 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2025 for nine therapeutic submarkets at world level:
- Human insulins and analogues
- Dipeptidyl peptidase-4 inhibitors (DPP-4)
- Biguanides
- Glucagon-like peptide-1 receptor agonists (GLP-1)
- Sulfonylureas.

And these treatment categories:
- Thiazolidinediones
- Alpha-glucosidase inhibitors
- Meglitinides
- Sodium-glucose co-transporter-2 inhibitors (SGLT2)
- Other agents (grouped).

You can assess the outlook for revenue expansion, learning where you can profit. Find the diabetes market size from 2015-2025. You can investigate the competition and rising sales. And you will examine technological, clinical and commercial possibilities.

You will also find top medicines’ revenue potentials.

Predictions of leading products’ sales – see what’s possible, and where you can gain
How will individual drugs for elevated blood sugar perform to 2025 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:
- Lantus
- Januvia
- NovoLog and NovoMix
- Levemir
- Humalog
- Victoza
- Janumet
- Humulin.

There you will find drugs and the years with highest predicted sales. You can also examine competitors. So discover what’s happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

Our work also gives geographical sales predictions.

National markets – what is the outlook for treatment demand and revenues?
In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2015 to 2025. See where, how and what’s possible.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
- United States (US)
- Japan
- EU leaders – Germany, France, the UK, Italy and Spain (EU5)
- BRIC nations –

Table Of Contents

Diabetes Drugs: World Industry, Market, RandD and Sales Forecasts 2015-2025
Table of Contents
1. Report Overview
1.1 Introduction to that Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered
1.7 Who is This Study For?
1.8 Research and Analysis Methods
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Global Diabetes Drug Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2015-2025
3.1 The World Diabetes Drug Market, 2014
3.1.1 Diabetes Treatment Market by Drug Class, 2014
3.1.2 Top Selling Diabetes Drugs, 2014
3.1.3 Generic Anti Diabetes Drugs, 2014
3.1.4 Top 10 Diabetes Drug Producers, 2014
3.2 World Diabetes Drugs Market: Revenue Forecast, 2015-2025
4. Human Insulin and Analogues Market, 2015-2025
4.1 Insulin and Insulin Analogues Drugs, 2014
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2015-2025
4.3 Insulin and Insulin Analogues: Market Trends, 2015-2025
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2015-2025
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast,
2015-2025
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2015-2025
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast,
2015-2025
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2015-2025
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast,
2015-2025
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2015-2025
5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2015-2025
5.1 DPP-4 Market, 2014
5.2 DPP-4 Inhibitors Revenue Forecast, 2015-2025
5.3 Januvia (Sitagliptin; Merck and Co.): Revenue Forecast, 2015-2025
5.4 Janumet (Sitagliptin and Metformin; Merck and Co.): Revenue Forecast, 2015-2025
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2015-2025
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2015-2025
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2015-2025
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2015-2025
6. Sulfonylureas Market, 2015-2025
6.1 Sulfonylureas Market, 2014
6.2 Sulfonylureas: Revenue Forecast, 2015-2025
6.3 Sulfonylureas: Market Trends 2015-2025
6.3.1 New Opportunities for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2015-2025
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2015-2025
6.6 Glucotrol (Glipizide; Pfizer): Revenue Forecast, 2015-2025
7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, 2015-2025
7.1 GLP-1 Receptor Agonists Market, 2014
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2015-2025
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2015-2025
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost the Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2015-2025
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025
8. Alpha-glucosidase Inhibitors Market, 2015-2025
8.1 Alpha-glucosidase Inhibitors Market, 2014
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2015-2025
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2015-2025
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2015-2025
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2015-2025
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2015-2025
9. Meglitinides Market, 2015-2025
9.1 Meglitinides Market, 2014
9.2 Meglitinides: Revenue Forecast, 2015-2025
9.2.1 Meglitinides: Market Trends, 2015-2025
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2015-2025
9.4 Sarlix (Nateglinide; Novartis): Revenue Forecast, 2015-2025
9.5 Glufast (Acarbose; Bayer): Revenue Forecast, 2015-2025
10. Thiazolidinediones Market, 2014
10.1 Thiazolidinediones Market Overview, 2014
11. Sodium-glucose Co-transporter-2 (SGLT2) Inhibitors Market, 2015-2025
11.1 SGLT2 Inhibitors Market, 2014
11.2 SGLT2 Revenue Forecast, 2015-2025
11.2.1 SGLT2 Market Trends, 2015-2025
11.3 Invokana (Canagliflozin; Johnson and Johnson): Revenue Forecast, 2015-2025
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2015-2025
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2015-2025
12. Biguanides Market, 2015-2025
12.1 Biguanides Market, 2014
12.2 Biguanides: Revenue Forecast, 2015-2025
12.2.1 Biguanides: Market Trends, 2015-2025
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck and Co): Revenue Forecast, 2015-2025
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2015-2025
12.5 Fortamet (Metformin; Shionogi and Co): Revenue Forecast, 2015-2025
13. National Markets for Diabetes Drugs, 2015-2025
13.1 Leading National Markets for Diabetes Drugs, 2014
13.2 Leading National Diabetes Drugs Market: Revenue Forecast,
2015-2025
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2015-2025
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast 2015-2025
13.4.1 Increased Governmental Investment Will Drive Market Growth
13.4.2 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.3 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2014
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market: Revenue Forecasts, 2015-2025
13.5.1.1 Germany: Disease Treatment Measures Require Improvement - Revenue Forecast, 2015-2025
13.5.1.2 Great Standard of Care and Regulatory Reforms in France - Revenue Forecast 2015-2025
13.5.1.3 Austerity Measures in Spain Discourage Companies - Revenue Forecast 2015-2025
13.5.1.4 UK: High Burden of Diabetes Costs on the UK NHS
13.5.1.5 Italy: Stable Market with Good Standards of Care - Revenue Forecast, 2015-2025
13.6 China: The World's Largest Diabetic Population - Revenue Forecast, 2015-2025
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2015-2025.
13.7.1 Focus on the Rural Population
13.8 Introduction of Novel Therapies in the Russian Federation - Revenue Forecast, 2015-2025
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas - Revenue Forecast, 2015-2025
13.9.1 Localized Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market RandD Pipeline, 2015
14.1 New Diabetes Drugs Approvals and Leading Companies' Developments, 2015
14.1.1 Novo Nordisk
14.1.2 Eli Lilly and Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (LY2963016 Eli Lilly and Boehringer Ingelheim): US Approval Delay May Trigger High Revenues
14.2.2 Insulin Glargine (U300 Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin. Will it Reach $1bn Sales?
14.3 Human Insulins and Analogues: Pipeline Developments, 2015
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 Basal Insulin Peglispro-BIL (Eli Lilly): Holding Promise - What Will More Testing Bring?
14.3.3 MK-1293 (Merck and Co. and Biogen Idec): Another Biosimilar of Lantus on the Way
14.3.4 OG217SC (Novo Nordisk)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex) Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck and Co.)
14.4.3 ARI-2243 (Arisaph)
14.5 GLP-1: New Approvals and Pipeline, 2015
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Does it have the Potential to Reach Blockbuster Status?
14.5.2 Tanzeum (Albiglutide; GSK)
14.5.3 Semaglutide (NN9535; Novo Nordisk)
14.5.4 Xultophy (formerly IDegLira; Novo Nordisk)
14.5.5 ITC650 (Intarcia Therapeutics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2015
14.6.1 Suglat (Ipragliflozin; Astellas Pharma/Kotobuki)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 Lusefi (Luseogliflozin; Taisho Pharmaceutical)
14.7 Other Anti Diabetes Drugs: Pipeline Developments, 2015
14.7.1 DM199 (DiaMedica)
14.7.2 DiaPep277 (Andromeda Biotech)
14.7.3 Glucokinase Activators
14.7.4 ZYGK1 (Zydus Cadila Healthcare)
14.7.5 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and RandD Analysis, 2015-2025
15.1 SWOT Analysis of the Diabetes Drug Market, 2015-2025
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to Copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers - Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues
16. Research Interviews
16.1 Interview with an Academic Involved in Diabetes RandD
16.1.1 The Insulin Drug Market
16.1.2 Novel Delivery Technologies
16.1.3 Future Developments and Market Prospects
16.2 Interview with James Anderson, Generex Biotechnology Corporation
16.2.1 The Current Diabetes Drug Market
16.2.2 Generex's Oral-lynâ„¢ Product and Buccal Drug Delivery
17. Conclusions from the Research and Analysis
17.1 The Diabetes Market - Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2015-2025
17.2.1 Insulin Will Continue to Dominate the Market
17.3 Regional Outlooks for That Market, 2015-2025
17.4 Future Opportunities

List of Tables
Table 1.1 Leading National Diabetes Drugs Market Forecast, 2015-2025 ($bn, AGR %), 2014-2025
Table 1.2 Foreign Currency Exchange Rates Utilised: Exchange Rate to $USD, 2014
Table 2.1 Types of Injectable Insulin, 2015
Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2015
Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2015
Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2015
Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2014
Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drug Class, 2014
Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2014
Table 3.4 Top 3 Human Insulin Producers: Sales ($m), 2014
Table 3.5 Top 10 Diabetes Drugs Producers: Sales ($m), 2014
Table 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn) by Drug Class, 2014-2019
Table 3.7 World Diabetes Drugs Market: Revenue Forecasts ($bn) by Drug Class,
2020-2025
Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 4.3 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 4.4 Top 3 Human Insulin Producers: Sales ($m), 2014
Table 4.5 Lantus: Drug Revenue Forecast ($bn), 2014-2025
Table 4.6 NovoLog: Drug Revenue Forecast ($bn), 2014-2025
Table 4.7 Humalog: Drug Revenue Forecast ($bn), 2014-2025
Table 4.8 Levemir: Revenue Forecast ($bn), 2014-2025
Table 4.9 Human Insulins Novo Nordisk: Revenue Forecast ($bn), 2014-2025
Table 4.10 NovoMix: Revenue Forecast ($bn), 2014-2025
Table 4.11 Humulin: Revenue Forecast ($bn), 2014-2025
Table 5.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 5.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 5.3 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 5.4 Januvia: Revenue Forecast ($bn), 2014-2025
Table 5.5 Janumet: Revenue Forecast ($bn), 2014-2025
Table 5.6 Galvus: Revenue Forecast ($bn), 2014-2025
Table 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025
Table 5.8 Nesina: Revenue Forecast ($bn), 2014-2025
Table 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025
Table 6.1 Sulfonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 6.2 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 6.3 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025
Table 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025
Table 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025
Table 7.1 GLP-1: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 7.2 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 7.3 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 7.4 Victoza: Revenue Forecast ($bn), 2014-2025
Table 7.5 Byetta: Revenue Forecast ($bn), 2014-2025
Table 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025
Table 8.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 8.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 8.3 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025
Table 8.5 Basen: Revenue Forecast ($bn), 2014-2025
Table 8.6 Glyset: Revenue Forecast ($bn), 2014-2025
Table 9.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 9.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 9.3 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 9.4 Prandin: Revenue Forecast ($bn), 2014-2025
Table 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025
Table 9.6 Glufast: Revenue Forecast ($bn), 2014-2025
Table 10.1 Thiazolidinediones: Revenues ($bn), 2014
Table 11.1 SGLT2 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 11.2 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 11.3 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 11.4 Invokana: Revenue Forecast ($bn), 2014-2025
Table 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025
Table 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025
Table 12.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 12.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 12.3 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025
Table 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025
Table 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025
Table 13.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2014
Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2014-2019
Table 13.3 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2020-2025
Table 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Table 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Table 13.6 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($bn) and Market Share (%) by Country, 2014
Table 13.7 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts ($bn), 2014-2019
Table 13.8 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2020-2025
Table 13.9 Germany: Revenue Forecast ($bn), 2014-2025
Table 13.10 France: Revenue Forecast ($bn), 2014-2025
Table 13.11 Spain: Revenue Forecast ($bn), 2014-2025
Table 13.12 United Kingdom: Revenue Forecast ($bn), 2014-2025
Table 13.13 Italy: Revenue Forecast ($bn), 2014-2025
Table 13.14 China: Revenue Forecast ($bn), 2014-2025
Table 13.15 India: Revenue Forecast ($bn), 2014-2025
Table 13.16 Russia: Revenue Forecast ($bn), 2014-2025
Table 13.17 Brazil: Revenue Forecast ($bn), 2014-2025
Table 14.1 FDA Approved Anti Diabetes Drugs, 2014
Table 14.2 Expected FDA Approvals for Anti Diabetes Drugs, 2015 and 2016
Table 17.1 The Global Diabetes Drugs Market: Overall Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025
Table 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2019 and 2025
Table 17.3 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025

List of Figures
Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2015
Figure 2.2 Diabetes Drugs Sub-market Segmentation, 2015
Figure 2.3 Diabetes Types and Classification, 2015
Figure 2.4 Diabetes Causes, 2015
Figure 2.5 Diabetes Regional Prevalence (population million), 2014
Figure 2.6 Diabetes Prevalence and Undetected Prevalence (%) by Region, 2014
Figure 2.7 World Number of Diabetics (population million), 2014-2025
Figure 3.1 World Diabetes Drugs Market: Market Share (%) by type of Medication, 2014
Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2014
Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2014
Figure 3.4 Top 10 Diabetes Drugs Producers vs Other Manufacturers: Market Share (%), 2014
Figure 3.5 Top 10 Diabetes Drugs Producers: Market Share (%), 2014
Figure 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2015
Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2014
Figure 4.2 Human Insulins and Analogues: Revenue Forecast ($bn), 2014-2025
Figure 4.3 Lantus: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.4 NovoLog: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.5 Humalog: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.6 Levemir: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.7 Human Insulins Novo: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.8 NovoMix: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.9 Humulin: Drug Revenue Forecast ($bn), 2014-2025
Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2014
Figure 5.2 DPP-4 Inhibitors: Sales ($bn) for Leading Drugs, 2014
Figure 5.3 DPP-4 Inhibitors: Revenue Forecast ($bn), 2014-2025
Figure 5.4 Januvia: Revenue Forecast ($bn), 2014-2025
Figure 5.5 Janumet: Revenue Forecast ($bn), 2014-2025
Figure 5.6 Galvus: Revenue Forecast ($bn), 2014-2025
Figure 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025
Figure 5.8 Nesina: Revenue Forecast ($bn), 2014-2025
Figure 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025
Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2014
Figure 6.2 Sulfonylureas: Sales ($bn) for Leading Drugs, 2014
Figure 6.3 Sulfonylureas: Revenue Forecast ($bn), 2014-2025
Figure 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025
Figure 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025
Figure 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025
Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2014
Figure 7.2 GLP-1: Sales ($bn) for Leading Drugs, 2014
Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($bn), 2014-2025
Figure 7.4 Victoza: Revenue Forecast ($bn), 2014-2025
Figure 7.5 Byetta: Revenue Forecast ($bn), 2014-2025
Figure 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025
Figure 8.1 Alpha-glucosidase Inhibitors: Revenue Sales ($bn), 2014
Figure 8.2 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2014
Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($bn), 2014-2025
Figure 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025
Figure 8.5 Basen: Revenue Forecast ($bn), 2014-2025
Figure 8.6 Glyset: Revenue Forecast ($bn), 2014-2025
Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2014
Figure 9.2 Meglitinides: Market Sales ($bn) for Leading Drugs, 2014
Figure 9.3 Meglitinides: Revenue Forecast ($bn), 2014-2025
Figure 9.4 Prandin: Revenue Forecast ($bn), 2014-2025
Figure 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025
Figure 9.6 Glufast: Revenue Forecast ($bn), 2014-2025
Figure 10.1 Thiazolidinediones: Sales ($bn), 2014
Figure 11.1 SGLT2 Inhibitors: Sales ($bn) for Leading Drugs, 2014
Figure 11.2 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2014
Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($bn), 2014-2025
Figure 11.4 Invokana: Revenue Forecast ($bn), 2014-2025
Figure 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025
Figure 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025
Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2014
Figure 12.2 Biguanides: Sales ($bn) for Leading Drugs, 2014
Figure 12.3 Biguanides: Revenue Forecast ($bn), 2014-2025
Figure 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025
Figure 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025
Figure 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025
Figure 13.1 The Global Diabetes Drugs Market: Revenues ($bn) by Region, 2014
Figure 13.2 Top 3 Global Markets vs BRIC Countries: Market Shares (%), 2014
Figure 13.3 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2014
Figure 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Figure 13.6 EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($bn) by Country, 2014
Figure 13.7 EU5 (Germany, France, UK, Italy, Spain) Countries: Market Shares (%) by Country, 2014
Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries Market Global and EU5 Market Share (%), 2014
Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2014-2025
Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($bn), 2014-2025
Figure 13.11 Germany: Revenue Forecast ($bn), 2014-2025
Figure 13.12 France: Revenue Forecast ($bn), 2014-2025
Figure 13.13 Spain: Revenue Forecast ($bn), 2014-2025
Figure 13.14 United Kingdom: Revenue Forecast ($bn), 2014-2025
Figure 13.15 Italy: Revenue Forecast ($bn), 2014-2025
Figure 13.16 China: Revenue Forecast ($bn), 2014-2025
Figure 13.17 India: Revenue Forecast ($bn), 2014-2025
Figure 13.18 Russia: Revenue Forecast ($bn), 2014-2025
Figure 13.19 Brazil: Revenue Forecast ($bn), 2014-2025
Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2015-2025
Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
Figure 17.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025
Figure 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025

Companies Listed
Actavis
Alphapharm
American Diabetes Association
Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
Andromeda Biotech
Arisaph
Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
Astellas Pharma
AstraZeneca
Bayer
Biocon
Blue Cross
Bristol-Myers Squibb
Biogen Idec
Boehringer Ingelheim
Boston Therapeutics
Chugai Pharmaceutical
Diabetes UK
DiaMedica
Diamyd Medical
Eisai
Eli Lilly
European Medicines Agency (EMA)
Express Scripts
Food and Drug Administration (US FDA)
Franco-Indian Pharmaceuticals
Furiex Pharmaceuticals
Genentech
Generex Biotechnology Corporation
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Google
Human Genome Sciences
Intarcia
International Diabetes Federation (IDF)
Janssen (subsidiary of JandJ)
Johnson and Johnson (JandJ)
Lupin
Kissei Pharmaceuticals
Kotobuki Pharma
Kowa
MannKind Corporation
Mascot Health Series
Merck and Co.
Merck Serono
Ministry of Health (MoH, Germany)
Ministry of Health, Labour and Welfare (MHLW, Japan)
MSD KK (Asian subsidiary of Merck and Co.)
Mylan
National Health Service (NHS, UK)
National Institute of Health and Clinical Excellence (NICE, UK)
Novartis
Novo Nordisk
Ono Pharmaceuticals
Oramed Pharmaceuticals
Patheon
Pfizer
Ranbaxy Laboratories
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus (bought by Salix Pharmaceuticals)
Servier
Shantha Biotechnics (acquired by Sanofi)
Shionogi Pharmaceuticals
Shreya Life Sciences
Stanford University School of Medicine
Sun Pharma
Takeda
Taisho Pharmaceutical
Teva Pharmaceutical Industries
Transdermal Specialities
United States Diabetes Prevention Program (DPP)
World Health Organization (WHO)
Yabao Pharmaceutical
Zydus Cadila

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.